武田公司的HYQVIA® 10% S.C.注射套件获得日本批准,为抗体缺乏患者提供新的治疗方法. Takeda's HYQVIA® 10% S.C. Injection Set gets Japan approval, offering new treatment for antibody-deficient patients.

Takeda的HyQVIA10%的S.C.注射装置在日本已被批准用于治疗患伽马球球血病或低伽马球球血症、导致低抗体和频繁感染的条件的病人。 Takeda's HYQVIA® 10% S.C. Injection Set has been approved in Japan for patients with agammaglobulinemia or hypogammaglobulinemia, conditions causing low antibodies and frequent infections. 这是日本首个促进皮下免疫球蛋白疗法，将免疫球蛋白与重组人透明质酸酶相结合，以减少更大剂量的频率。 This is the first facilitated subcutaneous immunoglobulin therapy in Japan, combining immune globulin with recombinant human hyaluronidase to allow larger doses less frequently. 根据两个阶段的第三阶段研究核准,它为病人提供了更灵活的治疗方案。 Approved based on two Phase 3 studies, it provides more flexible treatment options for patients.